Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of “Hold” by Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been assigned an average rating of “Hold” from the twenty-eight research firms that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $32.2963.

SRPT has been the topic of a number of research analyst reports. Loop Capital set a $25.00 target price on Sarepta Therapeutics in a report on Tuesday, March 3rd. Wedbush lowered their price target on Sarepta Therapeutics from $34.00 to $29.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Oppenheimer restated an “outperform” rating and set a $37.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, March 19th. Needham & Company LLC reiterated an “underperform” rating on shares of Sarepta Therapeutics in a research report on Thursday, March 26th. Finally, Wall Street Zen raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the sale, the director owned 1,765 shares in the company, valued at $30,040.30. This trade represents a 80.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 7.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Sarepta Therapeutics by 9.2% in the 4th quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock worth $254,167,000 after purchasing an additional 993,283 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 454.6% during the fourth quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after purchasing an additional 6,390,860 shares in the last quarter. Erste Asset Management GmbH boosted its stake in shares of Sarepta Therapeutics by 1.6% during the fourth quarter. Erste Asset Management GmbH now owns 2,728,945 shares of the biotechnology company’s stock valued at $58,727,000 after purchasing an additional 43,000 shares in the last quarter. Aberdeen Group plc grew its holdings in shares of Sarepta Therapeutics by 13.6% during the fourth quarter. Aberdeen Group plc now owns 2,251,593 shares of the biotechnology company’s stock worth $48,454,000 after purchasing an additional 268,829 shares during the last quarter. Finally, First Trust Advisors LP increased its stake in shares of Sarepta Therapeutics by 2.7% in the fourth quarter. First Trust Advisors LP now owns 1,992,577 shares of the biotechnology company’s stock valued at $42,880,000 after buying an additional 52,796 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $21.76 on Friday. The firm has a 50 day moving average of $18.69 and a 200-day moving average of $20.08. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $67.47. The company has a current ratio of 2.32, a quick ratio of 1.48 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $2.28 billion, a PE ratio of -2.58, a PEG ratio of 0.31 and a beta of 0.42.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The firm had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. During the same quarter in the prior year, the business posted $1.90 EPS. The business’s revenue was down 32.7% on a year-over-year basis. On average, equities research analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.